<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
72374-101-01
</NDCCode>
<PackageDescription>
1 SYRINGE, GLASS in 1 CARTON (72374-101-01) / 300 ug in 1 SYRINGE, GLASS
</PackageDescription>
<NDC11Code>
72374-0101-01
</NDC11Code>
<ProductNDC>
72374-101
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Nypozi
</ProprietaryName>
<ProprietaryNameSuffix>
Txid
</ProprietaryNameSuffix>
<NonProprietaryName>
Filgrastim-txid
</NonProprietaryName>
<DosageFormName>
INJECTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20241216
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
BLA
</MarketingCategoryName>
<ApplicationNumber>
BLA761126
</ApplicationNumber>
<LabelerName>
Tanvex BioPharma USA, Inc.
</LabelerName>
<SubstanceName>
FILGRASTIM
</SubstanceName>
<StrengthNumber>
300
</StrengthNumber>
<StrengthUnit>
ug/300ug
</StrengthUnit>
<Pharm_Classes>
Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2026-01-01
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20251231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20241216
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>